ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 70 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $612,265 | +18.6% | 53,473 | +6.5% | 0.00% | – |
Q2 2023 | $516,097 | +139.5% | 50,204 | +79.9% | 0.00% | – |
Q1 2023 | $215,496 | +67.0% | 27,914 | +59.0% | 0.00% | – |
Q4 2022 | $129,073 | +53.7% | 17,561 | +51.9% | 0.00% | – |
Q3 2022 | $84,000 | -25.0% | 11,562 | -12.4% | 0.00% | – |
Q2 2022 | $112,000 | +34.9% | 13,199 | +42.3% | 0.00% | – |
Q1 2022 | $83,000 | -34.6% | 9,277 | +1.4% | 0.00% | – |
Q4 2021 | $127,000 | +353.6% | 9,145 | +234.5% | 0.00% | – |
Q3 2021 | $28,000 | -6.7% | 2,734 | -17.8% | 0.00% | – |
Q2 2021 | $30,000 | -47.4% | 3,326 | -37.8% | 0.00% | – |
Q1 2021 | $57,000 | -98.8% | 5,350 | -98.6% | 0.00% | -100.0% |
Q4 2020 | $4,759,000 | +22561.9% | 377,723 | +15527.8% | 0.00% | – |
Q3 2020 | $21,000 | -47.5% | 2,417 | -40.7% | 0.00% | – |
Q2 2020 | $40,000 | – | 4,075 | +58114.3% | 0.00% | – |
Q1 2020 | $0 | – | 7 | -66.7% | 0.00% | – |
Q4 2019 | $0 | – | 21 | -16.0% | 0.00% | – |
Q3 2019 | $0 | -100.0% | 25 | -99.6% | 0.00% | – |
Q2 2019 | $29,000 | -35.6% | 6,879 | +5.2% | 0.00% | – |
Q1 2019 | $45,000 | +55.2% | 6,538 | -14.9% | 0.00% | – |
Q4 2018 | $29,000 | +314.3% | 7,684 | +641.0% | 0.00% | – |
Q3 2018 | $7,000 | -12.5% | 1,037 | 0.0% | 0.00% | – |
Q2 2018 | $8,000 | -27.3% | 1,037 | -28.1% | 0.00% | – |
Q1 2018 | $11,000 | -8.3% | 1,443 | +39.2% | 0.00% | – |
Q4 2017 | $12,000 | -58.6% | 1,037 | -59.1% | 0.00% | – |
Q3 2017 | $29,000 | – | 2,537 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |